VERNON W ANTHONY 4

What Happened
Vernon W. Anthony, a director of NovoCure Ltd (NVCR), received equity awards on 2026-06-03. The Form 4 shows (a) 11,610 restricted stock units (RSUs) acquired at $0.00 and (b) 16,999 derivative awards acquired at $0.00. These are grants (transaction code A) reported in a Form 4 filed 2026-06-05. The filing reports $0.00 as the acquisition price (typical for awards); it does not indicate any open-market purchase or sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (2 days later — appears timely under Form 4 rules).
• Awards: 11,610 RSUs (F1) and 16,999 derivative awards (F2). Both reported at $0.00 acquisition price.
• Vesting: F1 — RSUs vest 100% on the earlier of the first anniversary of the grant or the day before the 2027 annual meeting. F2 — Options (derivative awards) fully vest and become exercisable on the same schedule.
• Shares owned after the transaction: not specified in the provided excerpt.
• No sale, exercise-for-cash, or tax-withholding transaction is indicated in this filing.

Context
These are compensation-related grants (not open-market purchases or sales). RSUs and options typically vest over time; here both packages become fully vested by the earlier of the one-year anniversary or just before the 2027 annual meeting. Awards reported at $0 on Form 4 reflect grant accounting on the form and do not show the grant’s fair-market value or the company’s expense recognition.